Pharma

Your Article Summary

See Latest Articles

Dronedarone (Multaq): Benzofuran derivative approved to reduce the risk of CV hospitalization in patients with AF
Formulary , 08/10/09

Dronedarone is a benzofuran derivative with antiarrhythmic properties belonging to all 4 Vaughan–Williams classes. Dronedarone's mechanism of action is unknown. This agent was approved on July 2009, to reduce the risk of cardiovascular (CV) hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL) who have experienced a recent episode of AF/AFL, have associated CV risk factors, and are in sinus rhythm or will be cardioverted.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals